The trial was the first of its type to look into the action of liraglutide in the treatment of non-alcoholic steatohepatitis. (sciencedaily.com)
Study subjects who received a 3 - milligram (3 - mg) dose of liraglutide lost an average of 8 percent of their body weight (18.7 pounds), compared with just 2.6 percent (6.2 pounds) for subjects receiving a placebo, or «dummy» drug, the investigators reported. (sciencedaily.com)
The trial demonstrated that 48 weeks of treatment with liraglutide resulted in 4 out of 10 patients clearing evidence of NASH from their livers. (sciencedaily.com)